- Home
- ANIX
as 04-04-2025 4:00pm EST
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 84.7M | IPO Year: | 1987 |
| Target Price: | $9.00 | AVG Volume (30 days): | 67.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.07 - $4.20 | Next Earning Date: | 03-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Anixa Biosciences Inc. (ANIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baskies Arnold M | ANIX | Director | Jan 28 '25 | Buy | $2.82 | 5,000 | $14,100.00 | 120,000 | |
| Titterton Lewis H jr | ANIX | Director | Jan 23 '25 | Buy | $2.96 | 3,000 | $8,820.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 22 '25 | Buy | $3.01 | 2,000 | $6,020.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 21 '25 | Buy | $2.59 | 6,000 | $15,540.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 17 '25 | Buy | $2.57 | 10,000 | $25,700.00 | 932,334 | |
| Catelani Michael | ANIX | President, COO, & CFO | Jan 15 '25 | Buy | $2.15 | 9,289 | $19,971.35 | 44,500 | |
| KUMAR AMIT | ANIX | Chief Executive Officer | Jan 15 '25 | Buy | $2.23 | 43,000 | $95,890.00 | 559,925 |
Latest Anixa Biosciences Inc. News
ANIX Breaking Stock News: Dive into ANIX Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
MT Newswires
12 days ago
Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines
PR Newswire
13 days ago
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Benzinga
13 days ago
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines
MT Newswires
13 days ago
Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine
PR Newswire
14 days ago
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Benzinga
14 days ago
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine
PR Newswire
21 days ago
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Compare ANIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIX Anixa Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.